ReviewCurrent atherosclerosis reports2011
Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP?
Review in Current atherosclerosis reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of particulate matter air pollution on C-reactive protein: a review of epidemiologic studies.Reviews on environmental health · 2012Pooled it
- A randomized, double-blind clinical trial to evaluate the efficacy and safety of a fixed-dose combination of amlodipine/rosuvastatin in patients with dyslipidemia and hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2020Trial
- Trial
- Utility of pan-immune-inflammation index in the diagnosis of masked hypertension in patients with type 2 diabetes mellitus.Hormones (Athens, Greece) · 2025Article
- Effect of statins on arterial wall inflammation as assessed by 18F-FDG PET CT: an updated systematic review and meta-analysis.Journal of inflammation (London, England) · 2024Article
- Blood Pressure Patterns and Hepatosteatosis: Cardiometabolic Risk Assessment in Dipper and Non-Dipper Phenotypes.Journal of clinical medicine · 2024Article
- The Role of Curcumin in Modulating Vascular Function and Structure during Menopause: A Systematic Review.Biomedicines · 2024Review
- The effects of statins on the function and differentiation of blood cells.Archives of medical science : AMS · 2023Article
- Influence of lipid-lowering drugs on inflammation: what is yet to be done?Archives of medical science : AMS · 2022Article
- Effect of urban air pollution on CRP and coagulation: a study on inpatients with acute exacerbation of chronic obstructive pulmonary disease.BMC pulmonary medicine · 2021Article
- Metabolic and Vascular Effect of the Mediterranean Diet.International journal of molecular sciences · 2019Review
- EFFECTS OF OCCUPATIONAL STRESS ON THE ACTIVATION OF HEMOSTATIC AND INFLAMMATORY SYSTEM.Acta clinica Croatica · 2019Article
- Metabolic syndrome in hypertensive women in the age of menopause: a case study on data from general practice electronic health records.BMC medical informatics and decision making · 2018Article
- The association of high sensitivity C-reactive protein and incident Alzheimer disease in patients 60 years and older: The HUNT study, Norway.Immunity & ageing : I & A · 2018Article
- Novel Immune Mechanisms in Hypertension and Cardiovascular Risk.Current cardiovascular risk reports · 2017Review
- C-Reactive Protein: An In-Depth Look into Structure, Function, and Regulation.International scholarly research notices · 2014Review
- Possible involvement of PPARγ-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities.Molecular and cellular biochemistry · 2013Article
- The Role of Toll-Like Receptors in Diabetes-Induced Inflammation: Implications for Vascular Complications.Current diabetes reports · 2012Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
Abstract
Much evidence supports a pivotal role for inflammation in atherosclerosis. C-reactive protein (CRP), the prototypic marker of inflammation in humans, is a cardiovascular risk marker and may also promote atherogenesis. CRP levels are increased in metabolic syndrome and hypertension and confer increased risk of cardiovascular events in patients in these subgroups. Statins have been shown to lower low-density lipoproteins and CRP independently, and reduce cardiovascular events in subjects with and without metabolic syndrome and hypertension. In this review, we focus on the results from the primary prevention statin trial, Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER), which showed reductions in LDL, CRP, and cardiovascular events. Post-JUPITER, the new guidelines will now need to consider recommending high-sensitivity CRP testing to intermediate-risk metabolic syndrome patients and those with hypertension and intermediate risk so that we can better identify candidates at greater risk and reduce cardiovascular burden in these subjects with statin therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.